surmount-1 tirzepatide non-diabetic weight loss as Compared with Semaglutide for the Treatment of Obesity Tirzepatide once weekly for the

Clinical perspectives on the use of the GIP/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity - Frontiers in Endocrinology Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity - JAMA Internal Medicine Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes - New England Journal of Medicine Tirzepatide for Diabetes Improves Glycemic Control After Switch From GLP-1RA - Endocrinology Advisor Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension - Diabetes, Obesity and Metabolism

Some people also experience diarrhoea or more frequent bowel movements, although the precise mechanism by which GLP-1 receptor agonists cause diarrhoea is not fully understood and is likely to involve multiple factors

The SURPASS program (type 2 diabetes) enrolled more than 19,000 participants across 10 trials

Both Zepbound and Ozempic may cause common side effects such as nausea, diarrhea, constipation, and vomiting

Both are legitimate, FDA-approved options and both require a licensed clinician, proper medical evaluation and ongoing monitoring

Adderall is a central nervous system (CNS) stimulant